{'fraction_non_alphanumeric': 0.028128031037827354, 'fraction_numerical': 0.023278370514064017, 'mean_word_length': 4.830508474576271, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The clinical relevance of chemosensitivity testing in ovarian cancer.

The aim of this study was to assess the role of in vitro chemosensitivity testing in ovarian cancer using the MTT assay. Cells were separated from solid biopsy or ascitic fluid samples from 73 patients with ovarian adenocarcinoma, FIGO stage III to IV, on presentation. A 48 h drug exposure was followed by the MTT assay to determine sensitivity. Patients were treated by conventional regimens containing platinum. There was a marked variation in sensitivity to the platinum drugs between individual patients. Clinical data were available for 37 patients. Eleven out of seventeen (65%) patients in the sensitive group had a complete response to therapy, compared with 3 out of 20 (15%) in the resistant group (p = 0.005). The overall survival rates were 36% for the sensitive group compared with 18% for the resistant group (p = 0.37). This study suggests that chemosensitivity testing in ovarian cancer may be effective in improving initial clinical response.